Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521703 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4528434 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4530294 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4524581 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4524705 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4534560 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4520064 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4531985 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4533913 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA | |
| SCHEMBL4526229 | 0.90 | LPAR3 (0.61) | TYMSLPAR3LPAR2LPAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2015-10-22 | — | — | US | disclosed |
| US-9028845-B2 | Chimeric immunomodulatory compounds and methods of using the same-IV | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2423335-B1 | Chimeric immunomodulatory compounds and methods of using the same | DYNAVAX TECH CORP (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20140127255-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2014-05-08 | — | — | US | disclosed |
| US-8597665-B2 | Chimeric immunomodulatory compounds and methods of using the same-IV | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1404873-B1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | DYNAVAX TECH CORP (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120231039-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2012-09-13 | — | — | US | disclosed |
| US-8222398-B2 | Chimeric immunomodulatory compounds and methods of using the same-II | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2423335-A2 | Chimeric immunomodulatory compounds and methods of using the same | Dynavax Technologies Corporation (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8114418-B2 | Chimeric immunomodulatory compounds and methods of using the same—IV | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090317480-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-II | DYNAVAX TECHNOLOGIES CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7625872-B2 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080181909-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | DYNAVAX TECHNOLOGIES CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-7255868-B2 | Chimeric immunomodulatory compounds and methods of using the same—I | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20070049550-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-20040132677-A1 | Chimeric immunomodulatory compounds and methods of using the same-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-08 | — | — | US | disclosed |
| US-20030225016-A1 | Chimeric immunomodulatory compounds and methods of using the same - III | DYNAVAX TECHNOLOGIES CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030199466-A1 | For modulating an immune response | DYNAVAX TECHNOLOGIES CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20030175731-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | DYNAVAX TECHNOLOGIES CORPORATION | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199466-A1 | For modulating an immune response | IFNG, ICOS, CD47 | TYMS 1505/4885LPAR3 212/4885LPAR2 167/4885 |
| US-20080181909-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | TSLP, CD74, MICA | TYMS 417/4885LPAR3 537/4885LPAR2 983/4885 |
| US-20030175731-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | TSLP, CD74, MICA | TYMS 417/4885LPAR3 537/4885LPAR2 983/4885 |
| US-20140127255-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | ICOS, CD47, IL2 | TYMS 581/4885LPAR3 335/4885LPAR2 340/4885 |
| US-20040132677-A1 | Chimeric immunomodulatory compounds and methods of using the same-IV | ICOS, CD47, IL2 | TYMS 581/4885LPAR3 335/4885LPAR2 340/4885 |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | ICOS, CD47, IL2 | TYMS 581/4885LPAR3 335/4885LPAR2 340/4885 |
| US-20090317480-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-II | IL2, ICOS, CD47 | TYMS 696/4885LPAR3 602/4885LPAR2 149/4885 |
| US-20030225016-A1 | Chimeric immunomodulatory compounds and methods of using the same - III | CD47, ICOS, IL2 | TYMS 634/4885LPAR3 182/4885LPAR2 432/4885 |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | IFNG, ICOS, IL2 | TYMS 494/4885LPAR3 329/4885LPAR2 281/4885 |
| US-20120231039-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | ICOS, CD47, IL2 | TYMS 581/4885LPAR3 335/4885LPAR2 340/4885 |
| US-20070049550-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | TSLP, CD74, MICA | TYMS 417/4885LPAR3 537/4885LPAR2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.